CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group Limited is involved in the pharmaceutical industry, focusing on the development, production, and sale of finished drugs and bulk drugs. It offers products such as antibiotics and vitamin C.

msh id	HK:COM:CSPC
symbol	1.09K
name	CSPC Pharmaceutical Group Limited
homepage url	https://www.cspc.com.hk
country	CN
sector	Healthcare
industry	Drug Manufacturers - General
market	STOCKS
employee count	23.5K
crunchbase url	-
linkedin url	-
founders	-

market cap	9.33B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.04
growth cost of revenue	0.02
growth depreciation and amortization	0.01
growth ebitda	-0.02
growth ebitda ratio	0.02
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	-0.05
growth gross profit ratio	-0.02

1093

HK:COM:CSPC

CSPC Pharmaceutical Group Limited

Last Close

5.19

22/11 03:59

Market Cap

72.52B

Beta: -

Volume Today

21.11M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	3.46B
cost of revenue	3.46B
depreciation and amortization	157.6M
ebitda	1.15B
ebitda ratio	0.26
eps	0.07
eps diluted	0.07
operating expenses	2.15B
operating income	989.8M
operating income ratio	0.22

accounts receivables	-
capital expenditure	-267.77M
cash at beginning of period	1.48B
cash at end of period	1.69B
inventory	442.36M
working capital ttm	15.36B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-